Core Insights - Tempus AI, Inc. is recognized as a promising investment opportunity, particularly in the context of its advancements in precision medicine and partnerships with major pharmaceutical companies [1][5]. Group 1: Product Developments - Tempus AI introduced Paige Predict, an AI-driven digital pathology tool that analyzes H&E whole slide images to predict 123 biomarkers across 16 cancer types, enhancing clinical decision-making [2]. - The tool is built on a foundation model trained on data from over 200,000 patients and has been validated across multiple datasets, supporting the company's goal of advancing precision medicine [2]. Group 2: Financial Performance - Tempus reported a record Total Contract Value (TCV) exceeding $1.1 billion at the end of 2025, attributed to data agreements with over 70 customers, including major pharmaceutical companies like AstraZeneca and Pfizer [3][4]. - The company achieved a net revenue retention rate of 126%, indicating strong relationships with existing customers and a solid foundation for future growth [4]. Group 3: Strategic Vision - The Chief Financial Officer of Tempus highlighted that 2025 was a record year for the company's data and applications business, emphasizing the strong engagement with life sciences companies and the favorable positioning for continued growth in 2026 and beyond [5].

Core Insights - Nancy Pelosi's investment portfolio has significantly outperformed the S&P 500 over the past decade, with a cumulative return of 838% compared to the S&P 500's 256% [2] - Despite plans to retire, Pelosi's investment activities remain relevant, with her portfolio showing a 70.9% increase in 2024 and an 18% increase in 2025, both surpassing the S&P 500's respective gains [2] - Pelosi's net worth has grown to over $278 million, reflecting an average return of 16,930% since 1987, far exceeding the Dow Jones Industrial Average's 2,300% return during the same period [3] Investment Activity - Tracking the trading activities of Congress members has gained popularity, as it is believed they can outperform the market due to access to insider information [4] - Pelosi's recent financial disclosures indicate over $10 million in cumulative stock transactions, with significant repositioning in technology and energy sectors [5] Methodology for Stock Selection - The article identifies the 10 best stocks to buy based on Pelosi's recent public investment disclosures, utilizing Capitol Trades to track stock trading activity of U.S. politicians [8] - The stocks are ranked by the number of hedge funds holding stakes in them as of Q3 2025, reflecting a strategy to outperform the market by following top hedge fund picks [9] Notable Stocks - **AllianceBernstein Holding L.P. (NYSE:AB)**: This stock has rallied 10% year-to-date, outperforming the S&P 500, and offers an 8.21% dividend yield. The company has rebranded its NAV Lending team to enhance its private equity capabilities [10][11] - **Tempus AI, Inc. (NASDAQ:TEM)**: The company has confirmed its Immune Profile Score Test's predictive accuracy for patient outcomes and introduced an AI-powered digital pathology tool. Tempus reported a record Total Contract Value exceeding $1.1 billion, with significant customer engagement [15][19]

Core Insights - Advancements in artificial intelligence (AI) are significantly enhancing patient care, reducing healthcare costs, and improving outcomes in the medical technology industry [1] - Generative AI is transitioning from a conceptual promise to practical applications in medical technology [1] Industry Developments - AI is expediting all phases of research and development, including generative design, virtual testing, clinical trials, and regulatory documentation [2] - The FDA is promoting the development of innovative medical devices that incorporate AI [2] Company Performance: Tempus AI (TEM) - Tempus has seen a stock increase of 27.2% over the past year, while Doximity's stock has declined by 32.8% [6] - The company is developing advanced AI algorithms and diagnostic software, collaborating with Northwestern University's Abrams Center for Alzheimer's research [7] - Tempus has received two FDA 510(k) clearances for its cardiac imaging platform and ECG-Low EF software [8] - In Q3 2025, Tempus achieved positive adjusted EBITDA of $1.5 million, with gross profit rising to $209.9 million, a 98.4% year-over-year increase [11] - EPS for 2025 is projected to be a loss of 64 cents, reflecting a 59.5% improvement from 2024 [15] Company Performance: Doximity (DOCS) - Doximity is well-positioned for AI adoption, embedding AI across its workflows and benefiting from a recent acquisition of Pathway Medical Inc. [9][13] - The company reported a 55% adjusted EBITDA margin and a 39% net income margin in fiscal 2025, with $267 million in free cash flow [14] - EPS for fiscal 2026 is projected to be $1.56, indicating a 9.9% improvement from fiscal 2025 [16] Valuation Comparison - Tempus has a forward 12-month price-to-sales (P/S) ratio of 7.24, while Doximity's is 10.38, indicating Doximity is trading at a premium [17] Conclusion - Doximity appears better positioned than Tempus, with deep AI integration, strategic acquisitions, and strong profitability metrics [18] - Tempus is recognized for its expanding AI capabilities and recent profitability milestone, indicating long-term potential in precision medicine [19]

Group 1: Ark Invest's Strategic Moves - Ark Invest acquired shares in Tempus AI Inc., Kodiak AI Inc., and WeRide Inc. on Monday [1] - The firm significantly increased its position in Tempus AI by purchasing 1,192 shares through the ARK Genomic Revolution ETF and an additional 6,545 shares via the ARK Innovation ETF, totaling approximately $523,253 [2] - Ark Invest also made a notable purchase of 47,752 shares of Kodiak AI Inc. through the ARK Autonomous Technology & Robotics ETF, valued at approximately $427,380 [4] - The firm acquired 48,260 shares of WeRide Inc. through ARKQ, resulting in a total transaction value of approximately $417,449 [5] Group 2: Notable Transactions and Market Context - Former House Speaker Nancy Pelosi's spouse exercised 50 call options on Tempus AI, adding 5,000 shares to the portfolio, valued between $50,000 and $100,000 [3] - Tempus AI's stock closed at $67.63, while Kodiak AI's stock closed at $8.95, marking a decrease of 4.58% from the previous session [2][4] - WeRide Inc. reported that its fleet has surpassed 1,000 vehicles and announced integration with Tencent's WeChat platform [5]

Group 1 - The core viewpoint of the article highlights a significant rise in AI application software stocks in the US market on Monday, with notable gains for several companies [1] Group 2 - Cloudflare (NET.US) experienced a surge of over 9% [1] - Tempus AI (TEM.US) and Applovin (APP.US) both saw increases of over 4% [1] - Zoom Communications (ZM.US) rose by over 7% [1] - Unity Software (U.US) had a gain of over 3% [1]

Core Insights - Tempus Logix Auto Transport has launched an AI-driven instant car shipping calculator aimed at enhancing transparency and certainty in vehicle transport pricing [1][3][8] Company Overview - Founded in 2018 and headquartered in California, Tempus Logix has established itself as a top-rated vehicle shipping provider by focusing on reliability, clarity, and customer trust [3][7] - The company operates as a fully licensed and bonded broker, registered with the Federal Motor Carrier Safety Administration, and maintains an A+ rating with the Better Business Bureau [7] Product Features - The new AI calculator provides real-time, accurate pricing for various vehicle types and routes, addressing common issues like fluctuating estimates and hidden fees [1][4] - Unlike traditional quoting systems, the AI calculator evaluates multiple variables simultaneously, ensuring precise pricing for customers [4] - Customers are not required to make upfront payments to secure bookings, and a money-back guarantee is offered for any processing fees until a driver is assigned [5] Service Offerings - Tempus Logix provides standard nationwide transport as well as unique services such as guaranteed pickup options and shipping to and from Hawaii [6] - The company transports a diverse range of vehicles, including motorcycles, ATVs, UTVs, RVs, boats, and heavy equipment, catering to both individual consumers and commercial clients [6] Industry Impact - The introduction of the AI-powered calculator signifies a shift towards technology-driven transparency in the vehicle transport sector, enhancing customer experience from booking to delivery [8]

Industry Overview - The artificial intelligence (AI) in pathology market is projected to reach $1.15 billion by 2033, growing at a CAGR of 27.18% from 2025 to 2033, driven by demand for precision medicine, increasing chronic disease prevalence, and technological advancements in diagnostic tools [1] Company Developments - Tempus AI acquired Paige, a leading AI-driven digital pathology company, enhancing its capabilities with a proprietary dataset of nearly 7 million clinically annotated, digitized pathology slides [2] - Following the acquisition, Tempus launched Paige Predict, a suite of advanced digital pathology applications that analyze hematoxylin and eosin (H&E) whole-slide images to support informed testing decisions, predicting 123 biomarkers and oncogenic molecular pathways across 16 cancer types [3][7] - Labcorp entered a collaboration with Roche in 2025 to implement FDA-cleared VENTANA DP 600 and DP 200 slide scanners, enhancing efficiency and supporting AI integration in its anatomic pathology services [4] - Labcorp's Biopharma Laboratory Services added digital pathology capabilities and agreed to acquire select technical assets of Incyte Diagnostics' anatomic pathology business [5] - Quest Diagnostics introduced a new testing panel for amyloid brain pathology in symptomatic patients and acquired PathAI Diagnostics to accelerate AI adoption in digital pathology [6]

Core Insights - Tempus AI, Inc. has demonstrated resilience in the AI market, showing strong stock performance in 2025 and continuing this trend into 2026 [1] Company Performance - The company has had a strong start in 2026, indicating ongoing investor confidence despite market fears [1]

Tempus AI Trade - Ark Invest acquired a total of 13,532 shares of Tempus AI through the ARK Genomic Revolution ETF and ARK Innovation ETF, following a revenue surge of 83% year-over-year for 2025, driven by a 111% increase in diagnostics revenue [2] - The shares closed at $68.36, resulting in an investment of approximately $925,047, with an additional purchase of $5.85 million worth of shares made the previous day [3] WeRide Trade - Ark Invest purchased 166,029 shares of WeRide through the ARK Autonomous Technology & Robotics ETF, as WeRide expanded its global fleet to over 1,000 robotaxis [4] - The shares were acquired at a closing price of $9.05, totaling an investment of approximately $1.5 million [4] Roku Trade - Ark Invest sold 14,885 shares of Roku through the ARK Next Generation Internet ETF at a closing price of $107.23, amounting to approximately $1.6 million [5] - This sale occurred amid mixed analyst forecasts, with Jefferies upgrading Roku to Buy and raising its price target from $100 to $135, indicating an improved outlook for the company [5] Other Key Trades - Ark Invest sold 161,683 shares of Beam Therapeutics Inc. across ARKG and ARKK, 32,227 shares of Unity Software Inc. through ARKW, and 29,533 shares of GitLab Inc. through ARKW [7] - Additionally, the company bought 7,175 shares of Kodiak AI Inc. through ARKQ [7]

Core Insights - Digital healthcare platforms are expanding in consumer wellness and precision medicine, with Hims & Hers Health, Inc. (HIMS) focusing on consumer-first services and Tempus AI, Inc. (TEM) leveraging AI for precision medicine [1][2] Company Overview - HIMS operates a subscription-based platform providing personalized treatments through telehealth and pharmacy services, while TEM utilizes AI on clinical and molecular data for healthcare providers [1][2] - HIMS is expanding into lab testing and diagnostics, enhancing its service offerings in weight management, hormone health, and preventive care [6][7] - TEM is building a multimodal dataset for diagnostics and clinical decision-making, enhancing its value to healthcare providers and researchers [10][12] Stock Performance & Valuation - HIMS has underperformed with a 40.4% decline over the past three months, while TEM has decreased by 24.9% [3] - HIMS is trading at a forward price-to-sales (P/S) ratio of 2.35X, in line with the Medical sector average, whereas TEM's P/S ratio is 7.35X, above the sector average [4] Growth Drivers for Hims & Hers - HIMS is broadening its portfolio, which is expected to increase its addressable market and customer engagement [7] - The company's vertically integrated, data-driven care model enhances personalized treatment plans and quality control [8] - Global expansion and strategic capital deployment are expected to sustain long-term growth and recurring revenue [9] Growth Drivers for Tempus AI - TEM's data advantage from genomic testing and clinical data collection supports its diagnostic offerings and licensing business [10] - Increased adoption of TEM's diagnostic tools reflects integration into clinical workflows, bolstered by regulatory clearances [11] - AI-driven product expansion positions TEM as a technology partner, enhancing its long-term growth narrative [12] Earnings Projections - The Zacks Consensus Estimate for HIMS suggests a 16.8% improvement in EPS for 2026 compared to 2025 [15] - The Zacks Consensus Estimate for TEM indicates a 71.6% improvement in loss per share for 2026 compared to 2025 [18] Price Targets - Analysts project an average price target of $43.85 for HIMS, indicating a potential increase of 51.8% from the last close [20] - For TEM, the average price target is $87.92, suggesting a 34.6% increase from the last close [21] Investment Perspective - HIMS is viewed as a more favorable investment due to its consumer-focused model and expanding service offerings, despite being rated as a Zacks Rank 4 (Sell) [22] - TEM, also rated as Zacks Rank 4, has a compelling long-term growth narrative but trades at a higher valuation, indicating less margin for error [25][26]